ADAM-10 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAM-10 (UniProt O14672), HEK293-expressed. Validated for ectodomain sheddase activity assays, inhibitor IC50 determination, and antibody validation. Pairs with TPB antibody RP-ADAM10.
Expression system
HEK293
Cat. #
REC-ADAM10

In stock

SKU
REC-ADAM10
$498.00

Target Overview

ADAM-10 (Disintegrin and metalloproteinase domain-containing protein 10; UniProt O14672) is a type I transmembrane zinc metalloprotease encoded by the ADAM10 gene. The full-length human protein spans 748 amino acids and contains a signal peptide, prodomain, metalloprotease domain (harboring the HEXXH catalytic motif), disintegrin domain, cysteine-rich domain, EGF-like domain, transmembrane helix, and short cytoplasmic tail. This recombinant is produced in HEK293 cells, a mammalian expression system that supports the N-linked glycosylation patterns and disulfide-bond architecture critical for native-like folding and catalytic competence of the metalloprotease domain. The primary biochemical function of ADAM-10 is ectodomain shedding: proteolytic release of the extracellular portions of transmembrane proteins at or near the plasma membrane. Characterized substrates include the amyloid precursor protein (APP; constitutive and regulated α-secretase cleavage), Notch receptors (mediating lateral inhibition signaling), TNF (cleavage at Ala76–Val77), JAM3, CD44, CDH2, ephrin-A2, heparin-binding EGF-like growth factor, L1, and the cellular prion protein. Substrate selectivity is regulated in part by association with TspanC8 family tetraspanins, which also govern ER exit and intracellular trafficking. In the laboratory, the recombinant metalloprotease domain is the standard tool for fluorescent peptide substrate cleavage assays, small-molecule inhibitor IC50 determination, and kinetic characterization (kcat/Km). Researchers also use the recombinant as a positive-control antigen in Western blot and immunohistochemical antibody validation experiments. Researchers validating antibody lot-to-lot consistency or establishing detection sensitivity can pair this recombinant directly with the matched Triple Point Biologics antibody (RP-ADAM10).

Background

ADAM-10 has been studied extensively as a central sheddase across multiple biological systems, with its substrate repertoire placing it at the intersection of neuroscience, oncology, immunology, and vascular biology research programs. In neurodegeneration research, ADAM-10 is characterized as the principal constitutive α-secretase responsible for non-amyloidogenic cleavage of APP within the amyloid-β sequence, thereby precluding amyloid-β peptide generation. Cipriano GL et al. (2026, PMID 42278353) reviewed the molecular cross-talk between neuroinflammatory signaling pathways and secretase regulation in Alzheimer's disease research, positioning ADAM-10 as a target whose activity modulation is studied in the context of neuroinflammation-driven amyloid processing. This makes the recombinant protein a practical tool for in vitro α-secretase activity assays and for screening compound libraries intended for mechanistic studies in neurodegeneration models. In glioma biology, ADAM-10 has been studied as a shed of the synaptic adhesion molecule Neuroligin-3 (NLGN3). Tian YF et al. (2026, PMID 42312194) described an NLGN3–ADAM10 circuit linked to activity-dependent glioma growth mechanisms, connecting ADAM-10-mediated ectodomain release to AMPA receptor signaling. Recombinant ADAM-10 supports substrate cleavage assays using NLGN3-derived peptides relevant to these studies. In thrombosis and hemostasis research, ADAM-10 has been implicated in the proteolytic regulation of platelet surface proteins. Kaur A et al. (2026, PMID 42297145) examined shedding of TREM-Like Transcript-1 (TLT-1) from platelet surfaces, with ADAM-10 identified as a candidate sheddase in that regulatory pathway — a model system in which recombinant ADAM-10 activity assays and substrate-specificity profiling are relevant experimental approaches. ADAM-10 also functions as a sheddase for RAGE (Receptor for Advanced Glycation End-products), generating soluble sRAGE as a circulating decoy receptor. Perkins RK et al. (2026, PMID 42310923) reported associations between ADAM-10 sheddase regulation and circulating sRAGE levels in a metabolic disease research context, a system in which recombinant ADAM-10 is used to model enzymatic sRAGE release in cell-free biochemical assays. Across these research areas, the recombinant is used to establish enzymatic baselines, validate inhibitor selectivity, and generate defined amounts of shed ectodomain products for downstream mass spectrometry or ELISA quantification. It is not intended for clinical, diagnostic, or therapeutic use.

Applications

  • Fluorescent peptide substrate cleavage assay (e.g., Mca-PLAQAV-Dpa-RSSSR-NH2 or APP-derived peptides) to measure ADAM-10 metalloprotease activity
  • Small-molecule inhibitor IC50 determination and SAR profiling in cell-free enzymatic assays
  • Western blot positive-control antigen for anti-ADAM-10 antibody validation (pairs with TPB antibody RP-ADAM10)
  • Immunohistochemistry (IHC) standard for antibody sensitivity and specificity calibration
  • Ectodomain shedding reconstitution assays with recombinant substrates (e.g., NLGN3, RAGE, TLT-1 ectodomains)
  • Substrate identification and cleavage-site mapping by mass spectrometry in defined in vitro digestion reactions
  • Kinetic characterization (Km, kcat, kcat/Km) of ADAM-10 against peptide or protein substrates
  • Antibody lot-to-lot consistency testing and detection sensitivity standardization using a defined recombinant antigen

References

  1. Tian YF et al. Neuro-glioma activity-dependent growth mechanisms: an actionable circuit from NLGN3-ADAM10 to AMPA synapses. Transl Cancer Res. 2026. doi:10.21037/tcr-2025-1-2908. PMID: 42312194.
  2. Perkins RK et al. Aerobic Exercise Training Increases Circulating sRAGE in Adults With Type 2 Diabetes: Associations With Sheddase Regulation. Diabetes Obes Metab. 2026. doi:10.1111/dom.70995. PMID: 42310923.
  3. Kaur A et al. Platelet TREM-Like Transcript-1 (TLT-1) regulation in healthy donors and patients at risk of bleeding and thrombosis. J Thromb Haemost. 2026. doi:10.1016/j.jtha.2026.06.009. PMID: 42297145.
  4. Cipriano GL et al. Neuroinflammation and Secretase Regulation in Alzheimer's Disease: From Molecular Cross-Talk to Multi-Target Therapeutics. Int J Mol Sci. 2026. doi:10.3390/ijms27114824. PMID: 42278353.
  5. Du X et al. Reduced efficacy of an anti-toxin vaccine from senescence-driven attenuation of toxin virulence. JCI Insight. 2026. doi:10.1172/jci.insight.199834. PMID: 42258746.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Type I transmembrane; cell surface; Golgi → endosomes

Frequently Asked Questions

What molecular weight band should I expect for recombinant ADAM-10 on SDS-PAGE or Western blot?

The full-length human ADAM-10 polypeptide has a calculated MW of ~84 kDa, but the HEK293-expressed recombinant runs at approximately 95–105 kDa under reducing SDS-PAGE conditions due to N-linked glycosylation. The prodomain (~8 kDa) is removed during autocatalytic activation, so the mature active form typically resolves as a diffuse band in the 85–100 kDa range. If you observe a doublet, this reflects heterogeneous glycosylation — both bands are catalytically active. PNGase F treatment collapses the band to ~82 kDa, confirming glycan contribution.

Which processing form of ADAM-10 is this recombinant — zymogen or mature active enzyme?

This product is the mature, active form of human ADAM-10. During HEK293 expression and secretion, the prodomain is removed by furin-family proprotein convertases in the trans-Golgi network, yielding the catalytically competent metalloprotease. The recombinant encompasses the metalloprotease, disintegrin, cysteine-rich, and EGF-like domains. It is not a zymogen and does not require activation steps prior to use. The HEXXH catalytic motif is intact and zinc-coordinated, making this suitable for direct use in cleavage assays without any pre-activation protocol.

What substrates does recombinant ADAM-10 cleave and what fluorogenic peptide should I use for activity assays?

ADAM-10 cleaves multiple physiological substrates including APP (α-secretase site), Notch receptors (S2 cleavage), E-cadherin, and EphB2. For in vitro fluorogenic activity assays, the synthetic peptide Mca-KPLGL-Dpa-AR-NH2 (a generic MMP/ADAM substrate) is compatible, but the more ADAM-10-selective substrate Mca-PLAQAV-Dpa-RSSSR-NH2 is preferred. Excitation/emission at 320/405 nm. Run assays in 25 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM CaCl2, 0.05% Brij-35. Starting enzyme concentration of 0.5–5 nM with 10–50 µM substrate gives reliable linear signal.

What buffer conditions are optimal for recombinant ADAM-10 activity assays and does glycerol inhibit the enzyme?

ADAM-10 is active in 25 mM Tris-HCl pH 7.5–8.0, 150 mM NaCl, 5 mM CaCl2, 0.05% Brij-35. The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2) is fine for long-term stability, but dilute at least 1:5–1:10 into assay buffer before use to reduce glycerol to ≤2%, as higher concentrations modestly suppress catalytic rate. Avoid EDTA, EGTA, or 1,10-phenanthroline — these chelate the catalytic zinc and will abolish activity. DTT above 1 mM is also not recommended, as it can disrupt the disulfide architecture in the cysteine-rich domain.

What starting concentration of recombinant ADAM-10 should I use to measure inhibitor IC50 in a fluorogenic assay?

For IC50 determinations, use enzyme at a concentration well below the Km of your substrate — typically 0.5–2 nM recombinant ADAM-10 with 10 µM fluorogenic substrate. Running the enzyme at sub-Km substrate conditions satisfies the Cheng-Prusoff correction and ensures your measured IC50 approximates Ki. Include a no-enzyme blank and a DMSO vehicle control (≤0.5% DMSO final). GI254023X and INCB7839 serve as well-characterized reference inhibitors with reported ADAM-10 IC50 values of ~1–10 nM in comparable assay formats — useful for inter-run normalization.

Can I use recombinant ADAM-10 (REC-ADAM10) as a positive control for Western blot with the matched RP-ADAM10 antibody?

Yes — REC-ADAM10 and RP-ADAM10 are developed and validated together in the same lab specifically for this use case. Load 50–100 ng of recombinant ADAM-10 per lane alongside your cell lysate lanes. The RP-ADAM10 rabbit polyclonal (see /anti-adam-10-rabbit-polyclonal-antibody) detects a band at 95–105 kDa under standard reducing conditions. Use RP-ADAM10 at 1:1,000–1:2,000 dilution in 5% non-fat milk/TBST, with anti-rabbit HRP secondary at 1:5,000–1:10,000. The recombinant lane provides a clean, defined signal to confirm antibody specificity and calibrate exposure time relative to endogenous protein in your samples.

How much recombinant ADAM-10 should I load per lane as a Western blot positive control, and will it look the same as endogenous ADAM-10?

Load 50–100 ng per lane for a strong, unambiguous positive control band with RP-ADAM10. At 50 ng, signal is detectable without overloading. The recombinant runs at 95–105 kDa — the same range as endogenous ADAM-10 in HEK293, HeLa, or primary neuron lysates — so band alignment is direct and interpretable. Note that endogenous ADAM-10 may appear as a broader or slightly lower band in some cell types reflecting differences in glycan processing at individual N-glycosylation sites. Both represent correctly folded, processed protein.

How should I handle, dilute, and store recombinant ADAM-10 to maintain activity over time?

REC-ADAM10 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2. Store at -20°C in the single-use aliquots provided. Avoid repeated freeze-thaw cycles — each cycle can reduce specific activity by 10–20%. For dilution series, use assay buffer supplemented with 0.1% BSA as a carrier protein to prevent adsorption losses at low concentrations (sub-1 nM). Pre-chill tubes on ice before aliquoting. Once thawed, use within 24 hours and keep on ice. Purity is >90–95% by SDS-PAGE; endotoxin is <0.1 EU/µg by LAL, suitable for cell-based assays.

Validation imagery coming soon

Western blot validation figures for REC-ADAM10 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →